ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0034

Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis

Lyndsey Cole1, Sucai Liu2, Brendan Allen2, Marie Feser3, Kristen Demoruelle4, Kevin Deane5, Michael Holers3 and Kristine Kuhn6, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 6University of Colorado, Aurora, CO

Meeting: ACR Convergence 2024

Keywords: microbiome, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Subdoligranulum didolesgii, S. dido 7, is present in a subset of individuals who are at-risk for RA (termed ‘ARI’) and who have clinical RA, activates CD4+ T cells in humans with RA, and is bound by dual family IgA/IgG monoclonal antibodies derived from ARI. S. dido 7 translocates across the intestinal barrier and leads to inflammatory arthritis (IA) and RA-relevant antibodies in mono-colonized germ-free mice. Intestinal permeability and increased abundance of other bacteria such as Prevotella copri are also observed in ARI and RA. To link these observations to prospective development of RA, we hypothesized that intestinal barrier permeability, fecal S. dido 7, and additional dysbiosis will associate with transition from AR to RA.

Methods: Stool and sera were prospectively collected from 3 groups: 1) ARI, defined as serum CCP+ with no past nor current IA at baseline (n=64), 2) Early RA, defined as untreated individuals with CCP+ RA (2010 ACR/EULAR criteria) within 12 months of diagnosis (n=6), and 3) Controls, defined as healthy individuals without IA or RF/CCP (n=49). Longitudinal samples were collected from ARI over 5 years and sub-grouped as those who convert to IA/RA (converters) and those who did not (non-converters). Fecal S. dido 7 and serum CCP3, zonulin and sCD14 were measured by quantitative PCR and ELISA, respectively. Shotgun metagenomic sequencing of stool was performed via Illumina and processed via MetaPhlAn and HuMAnN.

Results: Baseline fecal concentration of S. dido 7 was 2.6-fold higher in ARI and 1.4-fold higher in early RA compared to controls, P=0.01, Table 1. Serum zonulin and sCD14 were lower in ARI compared to controls and RA, P< 0.01, Table 1. S. dido 7 negatively associated with zonulin and sCD14, Spearman r = -0.36 and -0.19, P < 0.01 and 0.04, respectively, and was positively associated with CCP3, r=0.2, P=0.03. Alpha diversity of the fecal microbiome did not differ across groups at baseline, but beta diversity was significantly different (Figure 1a); by pairwise comparison, there was no baseline difference between converters and non-converters. ARI exhibited a greater abundance of Prevotella, Phocaeicola, and Bacteroides genera and lower abundance of Bifidobacterium adolescentis compared to controls (Figure 1b). There was a trend for S. dido 7 levels with Dietzia cercidiphylli, r=0.31, P= 0.05. Longitudinally, at follow up closest to time of diagnosis with IA/RA (median 458 days from baseline), converters showed decreased fecal S. dido 7 and increased zonulin and sCD14 compared to baseline (Table 2).

Conclusion: Our data confirm that S. dido 7 is elevated in ARI. However, in converters, S. dido 7 concentration decreases over time (though not to the level of controls) in association with increased intestinal permeability. This is indicative of active immune regulation of this bacterium possibly leading to development of IA/RA. Although we confirm dysbiosis at baseline in ARI, including increased abundance of P. copri, ongoing analysis of longitudinal bacterial metagenomics data will determine additional bacterial abundance changes with conversion to IA/RA and potentially identify additional associations with intestinal permeability and S. dido 7.

Supporting image 1

Table 1: Baseline Characteristics and Comparisons Among Healthy Controls, At-Risk Individuals, and Early RA

Supporting image 2

Table 2: Description of and Comparison Between Baseline and Follow up Samples in At-Risk Converters

Supporting image 3

Figure 1: Beta Diversity Across Participant Groups and Differentially Abundant Species-Level Taxa Between Control and At-Risk Groups


Disclosures: L. Cole: Appleton Medical (spouse's employer), 3; S. Liu: None; B. Allen: None; M. Feser: None; K. Demoruelle: Boehringer-Ingelheim, 5, Gilead, 5, Pfizer, 5; K. Deane: Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 6, Gilead, 5, Inova, 6, 12, Material Support, ThermoFisher, 5, 6; M. Holers: None; K. Kuhn: Pfizer, 5, UCB, 2.

To cite this abstract in AMA style:

Cole L, Liu S, Allen B, Feser M, Demoruelle K, Deane K, Holers M, Kuhn K. Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/arthritogenic-subdoligranulum-s-dido-7-is-increased-in-individuals-at-risk-for-and-with-early-ra-and-decreases-over-time-during-development-of-inflammatory-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arthritogenic-subdoligranulum-s-dido-7-is-increased-in-individuals-at-risk-for-and-with-early-ra-and-decreases-over-time-during-development-of-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology